ReviewJournal of pain research2026
Effectiveness of Compression Therapy for the Prevention of Taxane-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the prophylactic efficacy of compression therapy for taxane-induced peripheral neuropathy (TIPN). Methods: Systematically searched Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, Wan Fang, CBM, and VIP databases from inception to January 30, 2026. Included Randomized clinical trial (RCT) and quasi-Randomized clinical trials (quasi-RCTs). Two investigators independently screened studies, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool (RoB 1.0) for RCTs and the Joanna Briggs Institute (JBI) critical appraisal checklist for quasi-RCTs. Data were analyzed using Rev Man version 5.3, with subgroup analyses conducted according to study design, chemotherapy regimen, compression modality, and chemotherapy cycles. Results: Eleven studies were included, comprising six RCTs and five quasi-RCTs and involving a total of 737 patients. Compression therapy reduced overall TIPN incidence (RR=0.63, 95% CI: 0.47-0.83) and the incidence of CTCAE grade ≥2 and PNQ grade ≥D sensory and motor neuropathy. The single quasi-RCT assessing overall TIPN also reported a lower incidence with compression therapy (1/94 vs 10/94). Among the quasi-RCTs, compression therapy reduced CTCAE grade ≥2 motor neuropathy (RR=0.56, 95% CI: 0.35-0.89), whereas the sensory and PNQ outcomes were not statistically significant. CIPNAT scores were lower with compression therapy (MD=-34.72, 95% CI: -52.16 to -17.29). No subgroup differences were found by chemotherapy regimen, compression modality, or number of chemotherapy cycles. Compression therapy was generally well tolerated. Conclusion: Compression therapy may reduce the incidence of TIPN, but the findings should be interpreted cautiously because of the inclusion of quasi-RCTs, limited blinding, and heterogeneity in outcome measures. Further well-designed randomized controlled trials are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.